scholarly journals Compliance with and response to hepatitis B vaccination in remaining quilombo communities in Central Brazil

2009 ◽  
Vol 25 (4) ◽  
pp. 738-742 ◽  
Author(s):  
Ana Rita C. Motta-Castro ◽  
Selma A. Gomes ◽  
Clara F. T. Yoshida ◽  
Juliana C. Miguel ◽  
Sheila A. Teles ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Geometric Mean ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Hepatitis B Virus Infection ◽  
Education Programs ◽  
Central Brazil ◽  
Vaccination Scheme ◽  
B Virus ◽  
Male Sex

Compliance with and responses to the hepatitis B vaccine were evaluated in remaining quilombo communities in Central Brazil. A total of 708 individuals who were susceptible to hepatitis B virus infection were invited to participate in the hepatitis B vaccination program in eight communities. Although 567 (80%) individuals received the first dose, only 198 (28%) complied with the full vaccination scheme. Of 148 subjects who agreed to be tested for anti-HBs, 123 (83.1%; 95%CI: 75.9-88.6) responded to the vaccine. A geometric mean titer of 512mIU/mL (95%CI: 342.5-765.3) was found. Male sex and older age were independently associated with non-response. Additional health education programs and alternative hepatitis B vaccine schedules are needed to improve the vaccination coverage in these communities in Central Brazil.

Comparison of Higher-Dose Intradermal Hepatitis B Vaccination to Standard Intramuscular Vaccination of Healthcare Workers

2000 ◽  
Vol 21 (4) ◽  
pp. 264-269 ◽  
Author(s):  
Elizabeth A. Henderson ◽  
Thomas J. Louie ◽  
Karam Ramotar ◽  
Donna Ledgerwood ◽  
Karen Myrthu Hope ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Geometric Mean ◽  
Cost Effective ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Random Allocation ◽  
Intradermal Vaccination ◽  
B Virus ◽  
Microparticle Enzyme Immunoassay

Objective.To compare the immunogenicity of hepatitis B vaccine administered via intradermal (ID) versus intramuscular (IM) route.Methods:Subjects chose either to specify the route of immunization or to undergo random allocation to vaccination by the ID (0.15 mL) or the IM (1.0 mL) route. Yeast-derived recombinant hepatitis B vaccine was given at 0, 30, and 180 days. Hepatitis B surface antibody (HBsAb) and hepatitis B core antibody (HBcAb) were measured by microparticle enzyme immunoassay.Results:763 subjects were enrolled. Baseline screening identified 65 subjects (8%) who were positive for HBsAb or HBcAb. Vaccination was completed by 590 (85%) of 698 enrollees (370 ID, 220 IM). Seroconversion rates (geometric mean titers [GMT]>0 IU/mL HBsAb) for those vaccinated ID were 99% and 96% for screening at 9 months and 1 year post-vaccination, respectively; subjects vaccinated intramuscularly had similar rates of 95% and 96%. Seropositivity rates (GMT ≥ 10 IU/mL HBsAb) showed a similar pattern, with 95%, 92%, and 73% at 9 months and 1 and 2 years, respectively, for those vaccinated ID, and 94%, 93%, and 81% for those having IM vaccination. GMT for HBsAb was significantly higher for individuals vaccinated IM than for those vaccinated ID (P<.0001). The GMT ratio for the IM and ID routes decreased over time, being 9.3 at 9 months, 7.8 at 1 year, and 5.9 at 2 years. An unanticipated side effect of intradermal vaccination was skin discoloration at injection sites, which persisted for at least 2 years postvaccination. Two thirds (112/166) of respondents reported that they would have selected the ID route despite the discoloration.Conclusions:Higher-dose ID vaccination (3 vs 1 μg per injection) uses one sixth of the dose required for standard IM vaccination. It is a cost-effective way to vaccinate populations against hepatitis B virus, but the long-term efficacy of the ID route must still be investigated.

Mothers and Hepatitis B

PEDIATRICS ◽  
1983 ◽  
Vol 72 (2) ◽  
pp. 265-265
Author(s):  
Philip Rosenthal
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Immune Deficiency Syndrome ◽  
Deficiency Syndrome ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Virus Infection ◽  
Chronic Hepatitis B Virus ◽  
B Virus ◽  
Acquired Immune Deficiency

I read with interest the commentary on prevention of chronic hepatitis B virus infection.1 An important issue that was not discussed concerns the use of the hepatitis B vaccine and transmission of the newly recognized acquired immune deficiency syndrome (AIDS). The etiology of AIDS is unknown. AIDS occurs among the populations that donate plasma for hepatitis B vaccine manufacture.2,3 The safety of plasma donated for hepatitis B vaccine by persons with chronic hepatitis B who may have unrecognized or early AIDS is not known.

Epidemiological and molecular analysis of hepatitis B virus infection in manicurists in Central Brazil

2017 ◽  
Vol 90 (2) ◽  
pp. 277-281
Author(s):  
Larissa Cavaretto ◽  
Ana R.C. Motta-Castro ◽  
Sheila A. Teles ◽  
Fernanda Q. Souza ◽  
Wesley M. Cardoso ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Molecular Analysis ◽  
Hepatitis B Virus Infection ◽  
Central Brazil ◽  
B Virus

scholarly journals Effect of a Community-Based Hepatitis B Virus Infection Detection Combined with Vaccination Program in China

Vaccines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 19
Author(s):  
Xinyao Liu ◽  
Wuqi Qiu ◽  
Yan Liang ◽  
Wei Zhang ◽  
Qian Qiu ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Vaccination Rate ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Control Groups ◽  
Community Based ◽  
B Virus ◽  
Series Completion ◽  
And Control

Evidence on the effectiveness of hepatitis B virus (HBV) infection screening and vaccination programs remains rare in China. We used a quasi-experimental method, propensity score matching, to evaluate the effects of a community-based HBV infection detection combined with vaccination (HBVIDV) program in a pilot. Data were retrieved from the HBVIDV program implemented between July 2019 and June 2020. Outcomes were the difference between the treatment and control groups in hepatitis B vaccination (≥1 dose), hepatitis B vaccine series completion (≥3 doses), and serologic evidence of vaccine-mediated immunity. Altogether, 26,180 individuals were included, where 6160 (23.5%) individuals were assigned to the treatment group, and 20,020 (76.5%) individuals were assigned to the control group. After propensity score matching, 5793 individuals were matched. The rates of hepatitis B vaccination, hepatitis B vaccine series completion, and prevalence of vaccine-mediated immunity in the treatment and control groups were 29.0% vs. 17.8%, 22.1% vs. 13.1%, and 38.2% vs. 27.6%, respectively. The HBVIDV program was significantly associated with increased hepatitis B vaccination rate (OR, 1.884, 95% CI 1.725–2.057), hepatitis B vaccine series completion rate (OR, 1.872, 95% CI 1.696–2.065), and prevalence of vaccine-mediated immunity (OR, 1.623, 95% CI 1.501–1.755). The greater magnitude of association between HBVIDV program and outcomes was observed among adults aged 35–54 years and adults who live in rural areas. The HBVIDV program was effective in increasing the hepatitis B vaccination rate, hepatitis B vaccine series completion rate, and prevalence of vaccine-mediated immunity among adults in the pilot. Further focusing the program on special populations and regions may produce more effective results.

scholarly journals Epidemiology of hepatitis B virus infection in first-time blood donors in the southwestern region of Goiás, central Brazil

2010 ◽  
Vol 33 (1) ◽  
pp. 38-42 ◽  
Author(s):  
Giulena Rosa Leite Cardoso dos Anjos ◽  
Regina Maria Bringel Martins ◽  
Megmar Aparecida dos Santos Carneiro ◽  
Sandra Maria Brunini ◽  
Sheila Araujo Teles
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Blood Donors ◽  
Hepatitis B Virus Infection ◽  
Central Brazil ◽  
B Virus ◽  
First Time

A Hepatitis B Vaccination Program in a Community Teaching Hospital

1987 ◽  
Vol 8 (3) ◽  
pp. 102-107 ◽  
Author(s):  
Myron J. Tong ◽  
Ann M. Howard ◽  
Gary C. Schatz ◽  
Mark A. Kane ◽  
Deborah A. Roskamp ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Previous History ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Anamnestic Response ◽  
Low Level ◽  
B Virus ◽  
Fourth Dose ◽  
Hb Vaccine

AbstractPrior to offering the hepatitis B (HB) vaccine, a prescreen for hepatitis B virus (HBV) antibodies was conducted in a 565 bed hospital in Pasadena, California. Antibodies to the hepatitis B virus were detected in 14.5% of 1,745 employees tested. There was a significantly higher prevalence in those with a previous history of hepatitis, blood transfusions, exposure to nee-dlesticks, number of years in the same occupation, and in the same hospital work area. Employees of Asian extraction (33.3%) and blacks (23.1%) had a higher prevalence of antibodies to the hepatitis B virus than Hispanics (13.7%) and whites (10.2%). Anti-HBs was detected in 92.6% of 865 employees who received three doses of the hepatitis B vaccine. Only 28.6% of nonresponders receiving a fourth dose of hepatitis B vaccine produced anti-HBs. The nonresponders to the HB vaccine were older (average age 64.9 years) when compared to the responders (average age 37.5 years), and more males failed to produce anti-HBs after vaccination than females. Hepatitis B vaccination of the majority of individuals with either “low level” anti-HBs alone or anti-HBc alone did not elicit an anamnestic response after one dose of vaccine, implying that these “low level” antibodies are nonspecific and do not represent antiviral antibodies. Adverse reactions to the hepatitis B vaccine were minor and included a flulike syndrome, sore arm, and rash and swelling at the injection site. The reasons for nonparticipation were obtained from 179 individuals, and the main issue was concern about safety of the hepatitis B vaccine.

scholarly journals Seroconversion after Recombinant Hepatitis B Vaccination

1970 ◽  
Vol 11 (2) ◽  
pp. 143-150 ◽  
Author(s):  
Abhijit Guho ◽  
Md Abdul Ahad ◽  
Md Abdus Salam ◽  
Md Abdul Alim ◽  
AKM Enamul Haque ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Virus Infection ◽  
Recombinant Hepatitis ◽  
Protective Level ◽  
Significant Difference ◽  
B Virus ◽  
Study Population

Background: Hepatitis B virus infection is an important public health problem with significant morbidity andmortality. Recombinant hepatitis B vaccine for the prevention of hepatitis B virus infection is in practice in differentparts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine inEPI schedule since 2005.Materials and methods: This study was carried out to assess the seroconversion status among hepatitis Bvaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparentlyhealthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. Allindividuals constituting the study population were screened for HBsAg by Immunochromatographic strip test andonly HBsAg-negative persons were included for estimation of their anti-HBs titer.Results: Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level(>10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinatedcontrols had anti-HBs titers below the protective level. Regarding immune response developed among vaccinatedindividuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively.Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those whoreceived 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose.Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer foundin 85.88% male and 92.31% female individuals. There was no significant difference of anti-HBs titer between maleand female (p>0.05). Vaccinated individuals from lower socioeconomic condition have had comparatively low rateof protective antibody than people from middle and upper classes.Conclusion: Recombinant HB vaccine induces good level of protective immunity among vaccinated persons.Keywords: Hepatitis B; hepatitis B vaccine; seroconversion; BangladeshDOI: 10.3329/jom.v11i2.5461J MEDICINE 2010; 11 : 143-150

Sign in / Sign up

Export Citation Format

Share Document